Skip to content

Behavioral Pharmacology of THC and Beta-Myrcene

Behavioral Pharmacology of THC and Beta-Myrcene

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05432284
Enrollment
32
Registered
2022-06-27
Start date
2027-07-01
Completion date
2028-11-01
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Use

Brief summary

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

Detailed description

The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). Participants will complete 9 acute drug administration periods in which they will administer THC alone, myrcene alone, THC and myrcene together, or placebo. Subjective drug effects and vital signs will be assessed following drug administration. Each participant will receive all 9 dose conditions in a randomized order using a placebo controlled within-subject crossover design. The study will help us understand the individual and interactive effects of THC and b-myrcene, two common constituents found in cannabis.

Interventions

DRUGPlacebo

Placebo (ambient air)

DRUGTHC

Pure THC vapor

DRUGBeta-Myrcene

Pure beta-myrcene vapor

Sponsors

Johns Hopkins University
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

placebo controlled, double blind

Intervention model description

All participants will complete all dose conditions (study arms) in a randomized order

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. Have provided written informed consent 2. Be between the ages of 18 and 55 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission 5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. 6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2 7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg 8. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene). 9. Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75).

Exclusion criteria

1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit; 2. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. 3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 4. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 5. Cannabis use that is inconsistent with protocol requirements. 6. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). 7. Individuals with anemia or who have donated blood in the prior 30 days

Design outcomes

Primary

MeasureTime frameDescription
Self-reported Drug Effect as assessed by the Drug Effect Questionnaire (DEQ)6 hoursPeak rating (0-100) of Drug Effect on the DEQ, with 0 being no effect and 100 being maximum effect.

Secondary

MeasureTime frameDescription
Self-reported "Tired/Sleepy" as assessed by the Drug Effect Questionnaire (DEQ)6 hoursPeak rating (0-100) of Tired/Sleepy on the DEQ, with 0 being no effect and 100

Countries

United States

Contacts

CONTACTRyan Vandrey, PhD
rvandrey@jhmi.edu410-550-4036
CONTACTTory Spindle, PhD
tspindle@jhmi.edu410-550-0529
PRINCIPAL_INVESTIGATORRyan Vandrey, PhD

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026